Barr Ellison Solicitors – commercial property
Advertisement: Cambridge Network
Advertisement: EY mid
ARM Innovation Hub
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: Mobas mid banner
Advertisement: KISS
Advertisement: CPL mid banner
16 May, 2018 - 14:28 By Kate Sweeney

PredictImmune joins the Babraham Research Campus community

The Babraham Research Campus has welcomed PredictImmune to its growing and thriving community. 

PredictImmune is developing pioneering tools to guide physicians in the treatment of patients with immune-mediated disease, through prediction of long-term clinical prognosis. 

The company is currently developing its first product, a prognostic biomarker test, to address inflammatory bowel disease (both Crohn’s and ulcerative colitis). 

This technology, based on world-leading research emanating from the University of Cambridge, accurately identifies patients – at diagnosis – who are at risk of experiencing severe, relapsing disease and therefore likely to benefit from early biologics therapy. 

The company recently secured an additional £4.3 million investment from the Wellcome Trust to support a prospective multi-centre clinical trial of the prognostic biomarker test, having raised £4.7m Series A funding in May 2017 led by Parkwalk Opportunities Fund with co-investment from Cambridge Enterprise and Wren Capital. 

Executive chairman Andrew Sandham, said: “We are pleased to have secured high quality laboratory and office space at the Babraham Research Campus as we continue to expand our operations, in advance of launching our first diagnostic test for IBD.  

“The  campus provides an extremely supportive hub for biotechnology companies to build from start-up to commercialisation, with excellent proximity to clinical and academic collaborators and strong business networking.” 

Having taken laboratory space within the Maia Building, PredictImmune joins a community of over 60 commercial companies already located on campus, which includes Bicycle Therapeutics, Crescendo Biologics, Kymab, and RxCelerate. 

Derek Jones, CEO, Babraham Bioscience Technologies commented: “I’m delighted that PredictImmune has decided to locate here and particularly pleased to welcome Andy Sandham back to the campus in his role as PredictImmune’s executive chairman. 

“The fact that we see serial entrepreneurs returning time and again is a fantastic endorsement of the Babraham Research Campus as a great environment from which to start and grow a life science business.”

Newsletter Subscription

Stay informed of the latest news and features